3SBio obtains ex-China global legal rights to Apexigens anti-TNF mAb technology 3SBio Inc.

3SBio previously obtained the China privileges from Apexigen in 2006. 3SBio's anti-TNF mAb, designated SSS07, provides completed pre-clinical screening and demonstrated higher potency than the best-known available TNF inhibitors, including infliximab and adalimumab, potentially improving treatment options for patients with rheumatoid arthritis and other inflammatory illnesses. In March 2015, 3SBio initiated a dose-escalating Phase I trial for SSS07 in China . A Phase 1b trial can be scheduled to start in early 2016 using multiple doses in healthy people. ‘Dosing of the first cohort of Stage I trial individuals with SSS07 was a significant milestone towards our goal of introducing a safe, effective and inexpensive treatment for the estimated 17 million individuals who suffer from rheumatoid arthritis globally, including 4.5 to 5.0 million in China’, commented Dr.All authors vouch for the precision and completeness of the analyses shown and the adherence of the study and this report to the protocol. The complete protocol is available at NEJM.org.5-ml dose. Children 6 to significantly less than 36 months of age received 0.25-ml doses, and children 36 to significantly less than 72 months old received 0.5-ml doses. Control vaccines were meningococcal C conjugate vaccine , given in 0.25-ml doses in children 6 to less than 12 months old, and tickborne encephalitis vaccine , given in 0.5-ml doses in children 12 to less than 72 months old.